OmniAb (OABI) Jefferies Global Healthcare Conference summary

Business overview and industry trends

• Operates a licensing model providing innovative antibody discovery technologies to the pharmaceutical industry.

• Antibody-based medicines have higher clinical success rates, driving industry shift from small molecules.

• Growth in antibody discovery is accelerating due to regulatory changes and improved biological understanding.

• The company is positioned for growth, expanding its partner base and technology offerings.

• Mission is to enable rapid development of therapeutics by advancing drug discovery technologies.

Technology platform and innovation

• Offers a unique four-species transgenic animal platform (rats, mice, chickens, cows) for antibody generation.

• Launched OmniDab, a chicken-based platform for single-domain antibodies, attracting significant partner interest.

• AI and machine learning are integrated throughout the technology stack, including the OmniDeep suite.

• Screening platforms (xPloration, GEM) enable rapid, high-throughput discovery of antibodies, including for difficult targets.

• Ongoing innovation includes new scaffolds and workflow versatility initiatives.

Partnerships, pipeline, and financial model

• Ended Q1 with 80 active partners and 327 programs in development, with strong growth despite industry funding challenges.

• Over 30 clinical or approved programs leverage the technology, with 4–6 new clinical entries expected this year.

• Business model generates value through upfront fees, milestones, and royalties, with royalties tied to partner-filed patents.

• Over 300 patents issued worldwide; royalty streams extend as far as 2043, supported by growing partner patent filings.

• Focus remains on expanding the partnered pipeline, launching new technologies, and supporting stakeholders.